ARCHIVES

Phase II Elotuzumab Study Demonstrates 33 Months PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

NIH Objects To Big Response On Immunology RFPs, But NCI Will Continue Wide Distribution

November 1, 1974

Letter In Response To Hadley; RFA Available

July 7, 1995

ACS, SU2C Committ $20 Million For Lung Cancer Dream Team

January 31, 2014

Lymphatic Mapping Techniques Can Outperform “Watch-and-Wait”

February 28, 2014

Advisory Groups: Nominations Sought For Director’s Consumer Liaision Group

June 13, 1997

In Brief: Hopkins Wins SPORE in Gastointenstinal Cancers; Nurses Group Calls For Proposals

January 21, 1994